Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients

European Journal of Surgical Oncology

Volumn 36, Issue 12, 2010, Pages 1202-1210

  Fotopoulou, C ^a   Richter, R ^a   Braicu, E I ^a   Schmidt, S C ^a   Lichtenegger, W ^a   Sehouli, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cytoreductive surgery; Optimal tumor debulking; Ovarian cancer; Predictive factors; Tumor residuals

Indexed keywords

ADOLESCENT; ADULT; ADVANCED CANCER; ADVANCED PRIMARY EPITHELIAL OVARIAN CANCER; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; FEMALE; HUMAN; INFECTIOUS COMPLICATION; INTESTINE RESECTION; LUNG DISEASE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; OPERATION DURATION; OVARY CANCER; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SURGICAL MORTALITY; WOUND HEALING IMPAIRMENT; ABDOMINAL SURGERY; ANALYSIS OF VARIANCE; CARCINOMA; HYSTERECTOMY; LYMPHADENECTOMY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; OVARIECTOMY; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; RISK; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; HUMANS; HYSTERECTOMY; LYMPH NODE EXCISION; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; ODDS RATIO; OVARIAN NEOPLASMS; OVARIECTOMY; PERITONEAL NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 79952062502     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2010.09.008     Document Type: Article

References (48)

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6. (Pubitemid 26012496)
2. Armstrong DK, Bundy B,Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43. (Pubitemid 43048949)
3. Aletti GD, Gostout BS, Podratz KC, et al. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 2006;100:33-7. (Pubitemid 41815046)
4. Vernooij F, Heintz P,Witteveen E, et al. The outcomes of ovarian cancer treatment are betterwhen provided by gynecologic oncologists and in specialized hospitals: a systematic review.Gynecol Oncol 2007;105:801-12. (Pubitemid 46734206)
5. Eisenkop SM, Spirtos NM, Montag TW, et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203-9. (Pubitemid 23001329)
6. Paulsen T, Kjaerheim K, Kaern J, et al. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 2006;16(Suppl. 1):11-7.
7. du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16(Suppl. 8): viii7-viii12. (Pubitemid 41631227)
8. Bristow RE, Eisenhauer EL, Santillan A, et al. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007;104:480-90. (Pubitemid 46135675)
9. van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-34.
10. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351: 2489-97.
11. Colombo PE, Mourregot A, Fabbro M, et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol 2008.
12. Vergote I, Tropé C.G, Amant F, et al. Randomised EORTC-GCG/NCICCTG Trial comparing primary debulking surgery with neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IVovarian, fallopian tube and peritoneal cancer. 12th Biennial Meeting of the International gynecologic cancer Society. Bangkok, Thayland.
13. Harter P, du Bois A, Hahmann M, et alArbeitsgemeinschaft Gynaekologische Onkologie ovarian Committee; AGO ovarian cancer study group. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006;13(12):1702-10. (Pubitemid 44951480)
14. International Federation of Gynecology and Obstetrics. Changing in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987;156:263-4.
15. Sehouli J, Könsgen D, Mustea A, et al. ["IMO" eintraoperative mapping of ovarian cancer]. Zentralbl Gynakol 2003;125(3-4):129-35. [German].
16. Hou JY, Kelly MG, Yu H, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 2007;105(1):211-7. Epub 2007 Jan 18. (Pubitemid 46441463)
17. Brockbank EC, Ind TE, Barton DP, et al. Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer 2004;14(1):42-50. (Pubitemid 38280622)
18. Chi DS, Zivanovic O, Palayekar MJ, et al. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol 2009;112(1):6-10.
19. Jung DC, Kang S, KimMJ, Park SY, Kim HB. Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer. Eur Radiol 2009 Aug 6;. [Epub ahead of print].
20. Risum S, Høgdall C, Loft A, et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomographyea prospective study. Gynecol Oncol 2008;108(2):265-70. Epub 2007 Dec 4. (Pubitemid 351181445)
21. Bristow RE, Duska LR, Lambrou NC, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000;89(7):1532-40.
22. Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 2004;101(2):346-52. (Pubitemid 38890839)
23. Axtell AE, Lee MH, Bristow RE, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 2007;25(4):384-9. (Pubitemid 350002986)
24. Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 2005;96(2):301-6. (Pubitemid 40127125)
25. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993;11(1):166-72. (Pubitemid 23059991)
26. Salani R, Axtell A, Gerardi M, Holschneider C, Bristow RE. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2008;108(2):271-5.
27. Aletti GD, Dowdy SC, Gostout BS, et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg 2009;208(4):614-20.
28. Zivanovic O, Eisenhauer EL, Zhou Q, et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 2008 Feb;108(2):287-92. Epub 2007 Nov 13. (Pubitemid 351174284)
29. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006;103(3):1083-90. Epub 2006 Aug 4. (Pubitemid 44821338)
30. Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 2004;94(3):650-4. (Pubitemid 39194456)
31. Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2003;13(2): 120-4. (Pubitemid 37055464)
32. Gilani MM, Karimi Zarchi M, Ghaemmaghami F, Behtash N, Mousavi AS, Ansaripoor S. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Gynecol Oncol 2007;105(3):780-3. Epub 2007 Apr 11. (Pubitemid 46734210)
33. Arits AH, Stoot JE, Botterweck AA, Roumen FJ, Voogd AC. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Int J Gynecol Cancer 2008;18(4): 621-8. Epub 2007 Sep 14. (Pubitemid 352020153)
34. Kim HS, Kim JW, Cho JY, et al. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI. Eur J Surg Oncol 2009;35(8):870-6. Epub 2009 Jan 29.
35. Obeidat B, Latimer J, Crawford R. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol Obstet Invest 2004;57(3):153-6. Epub 2004 Jan 15. (Pubitemid 38410702)
36. Barlow TS, Przybylski M, Schilder JM, Moore DH, Look KY. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer 2006;16 (2):496-500.
37. Fagotti A, Ferrandina G, Fanfani F, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 2006;13(8):1156-61. Epub 2006 Jun 21. (Pubitemid 44337976)
38. de Jong D, Eijkemans MJ, Lie Fong S, et al. Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma. Oncology 2007;72(5-6):293-301. Epub 2008 Jan 14. (Pubitemid 351238140)
39. Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K, Morgan A. Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol 2004;95 (2):377-83. (Pubitemid 39445875)
40. Everett EN, Heuser CC, Pastore LM, et al. Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer. Am J Obstet Gynecol 2005;193(2):568-74. discussion 574-576.
41. Gerestein CG, Nieuwenhuyzen-de Boer GM, Eijkemans MJ, Kooi GS, Burger CW. Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Cancer 2009 Nov 7;. [Epub ahead of print].
42. Gillette-Cloven N, Burger RA, Monk BJ, et al. Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer. J Am Coll Surg 2001;193(6):626-32. (Pubitemid 33111534)
43. Mourton SM, Temple LK, Abu-Rustum NR, et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 2005;99(3):608-14. Epub 2005 Sep 8. (Pubitemid 41686544)
44. Hoffman MS, Zervose E. Colon resection for ovarian cancer: intraoperative decisions. Gynecol Oncol 2008;111(2 Suppl):S56-65. Epub 2008 Oct 2. Review.
45. Richardson DL, Mariani A, Cliby WA. Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol 2006;103:667-72. (Pubitemid 44604496)
46. Konishi T, Watanabe T, Kishimoto J, Nagawa H. Risk factors of anastomotic leakage after surgery for colorectal cancer: results of prospective surveillance. J Am Coll Surg 2006;202:439-44. (Pubitemid 43356218)
47. Fotopoulou C, Savvatis K, Steinhagen-Thiessen E, Bahra M, Lichtenegger W, Sehouli J. Primary radical surgery in elderly patients with epithelial ovarian cancer: analysis of surgical outcome and longterm survival. Int J Gynecol Cancer 2010;20(1):34-40.
48. Sehouli J, Senyuva F, Fotopoulou C, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol 2009;99(7):424-7.